English | Spanish
ecancer
Login Register
The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+ -
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1510]
News [3613]
Articles [292]
Editorials [9]
Conferences [72]
elearning [23]
Liquid biopsy detects DNA markers in advanced breast cancer within five hours
Liquid biopsy detects DNA markers in advanced breast cancer within five hours
A potentially more effective treatment for HER2 mutant metastatic breast cancer
A potentially more effective treatment for HER2 mutant metastatic breast cancer
Contrast-enhanced mammography vs MRI: Neoadjuvant therapy response in breast cancer
Contrast-enhanced mammography vs MRI: Neoadjuvant therapy response in breast cancer
Breast cancer mainly spreads at night
Breast cancer mainly spreads at night
NICE recommends abemaciclib in combination with endocrine therapy for adjuvant treatment of HR+/HER2- early breast cancer
NICE recommends abemaciclib in combination with endocrine therapy for adjuvant treatment of HR+/HER2...
Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers
Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy
ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cance...
ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low HER2 expression levels
ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast canc...
ASCO 2022: ASCO & WHO to collaborate on quality indicators for cancer facilities worldwide
ASCO 2022: ASCO & WHO to collaborate on quality indicators for cancer facilities worldwide
<12345...362>

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Follow ecancer on Facebook
  • Follow ecancer on Twitter
  • Follow ecancer on Linkedin
  • Subscribe to the ecancer YouTube channel
© 2022 ecancer, all rights reserved
UK registered charity number: 1176307